Abstract: The present invention is concerned with a plant extract comprising a mixture of di-O-D-galactosyl-di-O-acylglyceride with phytosphingolipids and phospholipids, as well as with a method for the preparation thereof through a physical extraction in the presence of water and ethanol. Such an extract can be used, in particular, in pharmaceutical, cosmetic and food compositions.

Abstract: Polyenylphosphatidylcholine in combination with an alkanolamine are topically applied to treat skin wounds, promote healing, and minmize scar formation. Typical compositions contain from about 0.25% to about 12% of a polyenylphosphatidylcholine preparation obtained from natural sources such as soybean oil which contains at least about 25% by weight, preferably about 40% or more, dilinoeoylphosphatidylcholine, and from about 0.1% to about 10% by weight of an alkanolamine such as ethylaminoethanol, methylaminoethanol, dimethylaminoethanol, isopropanolamine, triethanolamine, isopropanoldimethylamine, ethylethanolamine, 2-butanolamine, choline, serine, or mixtures thereof. Dimethylaminoethanol is a particularly preferred alkanolamine. Tyrosine is an adjunct ingredient in many embodiments.

Abstract: The invention relates to use of (a) compounds of phosphorus containing at least partly lipophilic organic radicals together with (b) urea and/or urea derivatives in selected quantity ratios of (a) to (b) as a soil additive for biologically controlling plant-parasitic soil nematodes by strengthening the correspondingly antagonistic soil potential, more particularly by strengthening the growth of antagonistic and/or nematicidal rhizosphere bacteria and/or corresponding mycorrhiza strains—and at the same time strengthening the growth of cultivated plants in soil. The multicomponent mixtures which strengthen bacterial growth are preferably introduced into the region of the plant roots in the form of an aqueous preparation using plant-compatible emulsifiers before and/or during plant growth. Components (a) and (b) are used in such quantity ratios that the ratio by weight of C to N is no higher than 6:1 and preferably no higher than 5:1.

Abstract: Disclosed is a safe and effective hair-growing agent comprising a protein kinase C-specific inhibitor.

Abstract: A composition containing an antineoplastic alkylphospholipid, and an antineoplastic antiestrogen in a lipid vesicle; more particularly, the composition is a liposome composition which comprises (i) an antineoplastic alkylphospholipid,(ii) an antineoplastic water- or lipid-soluble antiestrogen associated in liposomal form with the antineoplastic alkylphospholipid, (iii) a nonneoplastic phospholipid, and optionally one or more of (iv) a sterol, (v) a positively or negatively charged lipid, and (vi) a PEG lipid.

Abstract: A pharmaceutical composition adapted for use as a spermicide, the composition comprising a gel-microemulsion comprising an oil-in-water microemulsion and a polymeric hydrogel. The gel-microemulsion can be used in a spermicidal method.

Abstract: An inventive and proprietary food supplement formula per unit to enhance the body's natural immune function against viral and infectious diseases and cancer.

Abstract: Disclosed herein is a stabilization method of nano-sized emulsion by using lecithin and tocopheryl derivatives represented by the following formula (I) and 1

Abstract: Our invention concerns a mixture of CLA glycerides, and/or CLA-fatty acids and or CLA-alkyl esters and another component, wherein the other component (=component A) is selected for its capacity to alleviate problems related to insulin resistance in mammals, using CLA rich diets and/or foods and/or food supplements using an appropriate in vitro test so that in at least one step of the in vitro test, as described in the text, an improvement in test results is obtained of at least 4% by the blend of the CLA derivative and component A when compared to the CLA derivative only.

Abstract: The present invention provides a composition containing an anti-acne effective amount of a combination of five components that work combinatorially to combat the acne condition as a whole. The compositions contain an anti-irritant component, an anti-inflammatory component, an adhesion inhibiting component, an sebum reducing component, and a sclareolide component. Both inflamed and non-inflamed lesions associated with the acne condition are reduced with a combination of the anti-irritant component, the anti-inflammatory component comprising at least a hoelen mushroom extract, the adhesion inhibiting component comprising at least a polysaccharide, the sebum reducing component comprising at least a pygeum extract, and the sclareolide component. The methods of the present invention treating the acne condition in a holistic manner.

Abstract: A synergistic insecticide is provided by the addition of sodium lauryl sulfate or lecithin to an essential oil, preferably an essential oil which has been deregulated by the Environmental Protection Agency, to enable independently inactive or relatively inactive materials to provide commercially acceptable insecticidal properties without the need for undesirable poisons that may be toxic to humans and pets.

Abstract: The present invention relates to a cosmetic or pharmaceutical composition for topical application to the skin afflicted with rosacea and treated with a retinoid. The composition for treating rosacea comprises an anti-irritating component and several other components for treating rosacea. The other components form a mixture of a salicylic acid, a phytosphingosine, green tea, hinokitiol, gorgonian extract, and polysaccharide. The invention also provides a method for decreasing the irritation on the skin caused by the heightened sensitivity experienced by skin suffering from rosacea. The other components are effective in treating the rosacea condition, but particularly, in treating the telangiectasic symptom of rosacea.

Abstract: The present invention provides a menthol derivative represented by the following Formula 1 and a method for preparing the menthol derivative. The menthol derivative represented by the Formula 1 is prepared by reacting menthol and phosphorous oxychloride with an equivalence ratio of 1:1˜1.3 in an organic solvent in the presence of organic base to obtain dichloro[5-methyl-2(mehtylethyl)cylclohexyloxy] phosphino-1-one; and reacting above obtained dichloro[5-methyl-2(mehtylethyl) cylclohexyloxy]phosphino-1-one with 3-amino propanol in the organic solvent in the presence of the organic; then hydrolyzing and crystallizing the product with polar organic solvent.

Abstract: Disclosed are compositions for promoting the production of laminin 5 in epidermic cells which contain a lysophospholipid having a C14-22 fatty acid residue or a preparation derived from soybeans as an active ingredient and which can be used in the fields of cosmetics and dermatology. These compositions may be used especially for the purpose of potentiating the skin.

Abstract: Novel GAVE1 polypeptides, proteins and nucleic acid molecules are provided. In addition to isolated, full-length GAVE1 proteins, isolated GAVE1 fusion proteins, antigenic peptides and anti-GAVE1 antibodies are provided. Moreover, GAVE1 nucleic acid molecules, recombinant expression vectors containing a nucleic acid encoding GAVE1, host cells into which the expression vectors have been introduced and nonhuman transgenic animals in which a GAVE1 gene has been introduced or disrupted are provided. Diagnostic, screening and therapeutic methods utilizing GAVE1 compositions or composition that detect GAVE1 also are provided. Methods for identifying GAVE1 agonists, antagonists, reverse agonists and the like are described.

Abstract: The present invention relates to the use of an active compound including a sphingoid base, a derivative of a sphingoid base, a salt of a sphingoid base, a ceramide or a mixture of two or more of these compounds for manufacturing a composition for topical application for inhibiting mammalian ceramidase activity in the skin and microbial ceramidase originating from micro-organisms present on the skin. The composition may further contain an amount of a compound capable of complexating divalent cations.

Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.

Abstract: A method for enhancing the oral bioavailability of a prodrug ester by formulating the ester as a non-emulsified formulation with lecithin; as well as a pharmaceutical composition of at least one antibiotic and lecithin in a non-emulsified formulation; a method of treating infections with the non-emulsified formulation, and a method for preparing tablets by direct compression of blends of drugs with lecithin are disclosed. Non-emulsified formulations include solids, tablets, capsules, lozenges, suspensions, elixirs and solutions, and exclude emulsions, liposomes, lipid matrix systems and micro-emulsions. A suitable prodrug ester is a cephalosporin &bgr;-lactam antibiotic such as cefditoren pivoxil, and a suitable non-emulsified formulation is a solid formulation.

Abstract: After interruption of blood supply to central nervous system tissue, cerebral edema sets in. It has been shown that restoring blood flow to injured areas of the central nervous system after the onset of edema does not result in blood reperfusing the tissue. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition is generally an amphipathic lipid in an oil solution. The method provides for withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected, and replacing that fluid with an approximately equivalent volume of the amphipathic lipid in oil composition. The treatment can be augmented with agents that suppress production of cerebrospinal fluid, or with other known agents.

Abstract: Negatively charged phospholipids, as well as compositions including negatively charged phospholipids and possibly carotenoids and/or antioxidants, for treating the eye are disclosed. In a preferred embodiment, a composition comprising at least one negatively charged phospholipid except cardiolipin is used to treat age-related macular degeneration. Methods for producing the negatively charged phospholipids, as well as methods for producing the compositions including negatively charged phospholipids and possibly carotenoids and/or antioxidants for treating age-related macular degeneration, are also disclosed.

Abstract: The invention describes the prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event.

Abstract: This invention provides novel methods of inhibiting one or more symptoms of atherosclerosis. Also provided are assays for compounds that will inhibit the progression and/or ameliorate one or more symptoms of atherosclerosis. The methods and assays are based, in part, on the discovery that oxidized LDL or components thereof induce strong upregulation of MAP kinase phosphatase-1 which, in turn, is associated with an “inflammatory response” characteristic of atherosclerotic plaque formation. Inhibition of MKP-1 inhibits one or more symptoms of this response, e.g. monocyte adhesion, monocyte chemotaxis, differentiation into macrophages, etc. Inhibition of MKP-1 thus provides an effective method of inhibiting symptoms of atherosclerosis.

Abstract: The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C.

Abstract: The present invention relates to the use of certain lysophospholipids to inhibit phospholipase D activity and the growth of tumor cells in a mammal.

Abstract: The present invention is directed to a method of treating patients with major depression by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g., a triacylglycerol, which releases free fatty acid after ingestion by a patient.

Abstract: The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

Abstract: The present invention provides a method of using conjugated nonadecadienoic acid (CNA), one of its derivatives, or a combination thereof to inhibit lipoprotein lipase activity associated with a cell, to control body fat in a human or non-human animal, to inhibit cyclooxygenase activity in a cell, to inhibit platelet aggregation in a human or non-human animal, and to prevent or treat a condition or disease related to platelet aggregation.

Abstract: A method to inhibit inflammation in a mammal is disclosed. The method includes administering to the mammal a composition comprising a phospholipid, which can be lysophosphatidic acid. The administration of a phospholipid is believed to down regulate expression of adhesion molecules on the surface of vascular endothelial cells and circulating leukocytes of the mammal.

Abstract: The co-administration of ubiquinone (coenzyme Q) with eicosapentaenoic acid, which may be supplemented with or replaced by one or more of the unsaturated fatty acids gamma-linolenic acid, dihomogamma-linolenic acid, arachidonic acid and stearidonic acid. The fatty acids docosahexaenoic acid and linoleic acid should be present in less than 10%.

Abstract: The use of phospholipids of animal origin, rich in unsaturated fatty acids of the n-3 series to produce a suitable dietetic and/or pharmaceutical preparation for improving or restoring good mood, fighting against depressive states, chronic fatigue syndrome and asthenia, as well as for attenuating hyperactivity syndrome which can be associated with vegetable oils rich in unsaturated fatty acids of the n-3 series and/or fish oil, and/or vitamins.

Abstract: A pharmaceutical formulation comprising a pharmaceutically active agent, which is insoluble or sparingly soluble in water and a sterol phosphocholine surfactant.

Abstract: The present invention features methods and compositions for transdermal administration. In one embodiment, the invention features methods and compositions for transdermal administration of an amine containing compound having biphasic solubility and/or an agent which enhances the activity of the amine containing compound having biphasic solubility, e.g., a muscle relaxant, to relieve pain.

Abstract: This invention relates to the topical treatment of the Carpal Tunnel Syndrome by the use of a selected protein kinase C inhibitor and an effective penetrating agent selected from Lecithin organogel or poloxamer 407 lecithin organogel.

Abstract: The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.

Abstract: The present invention provides methods for extracting anti-apoptotic compositions from various protein isolates and/or lipid mixtures with aqueous solutions not containing organic solvents. The compositions extracted by the methods can be used for a variety of purposes, including for therapeutic, nutritional and medicinal purposes.

Abstract: A method for reducing or eliminating cravings associated with habitual substance abuse by administering to a human a synergistic composition containing an effective amount of each of Glutamine, gamma aminobutyric acid, tyrosine, taurine, theanine, 5-hydroxtryptamine, phenylethylamine, phosphatidyl serine, phosphatidyl choline, inositol, thiamin, riboflavin, niacin, pyridoxin, folic acid, biotin, pantothenic acid, cyanocobalamin, chromium polynicotinate magnesium, and decosahexaenoic acid. The pharmaceutical composition can be administered after complete cessation of a given habit forming substance, or to nullify cravings and to reduce abuse of a given habit forming substance, without total and complete remittance prior to administration of the composition. Worthy of note, all constituents found in this composition may be derived by synthetic means, or from natural sources.

Abstract: The present invention relates to a compositions and methods for treating tinnitus. In preferred embodiments of the invention, muscurinic and/or opioid agents are administered to the affected ear in amount effective to relieve one or more tinnitus symptoms. A preferred agent is an anticholinesterase inhibitor, such as neoostigmine.

Abstract: Disclosed are methods and materials for visualizing or treating vasculature. The methods and materials in this invention relate to selective and non-invasive visualization, or treatment such as chemical occlusion, of vasculature in the mammalian eye. The methods utilize fluorescent dyes and tissue-reactive substances encapsulated within heat-sensitive liposomes which are subsequently heated to release the contents thereof at a pre-determined anatomical locus. The methods of this invention further utilize tissue-reactive agents which, when activated, are effective to cause localized tissue damage and occlusion of blood vessels and/or blood sinuses. The materials of this invention relate to diagnostic reagents and kits for visualizing or treating a mammalian blood vessel or sinus.

Abstract: Compositions and methods for enhancing paracellular permeability at an absorption site in a subject are disclosed. The method includes: (a) administering an effective amount of a phospholipase C inhibitor to a subject at a time in which enhanced paracellular permeability is desired; and (b) enhancing paracellular permeability in the subject at the absorption site through the administering of the effective amount of the phospholipase C inhibitor. The disclosed compositions and methods provide enhanced absorption of a hydrophilic drug in a subject.

Abstract: The present invention relates to complexes of proanthocyanidin A2 and one or more phospholipids, pharmaceutical compositions containing the complex of proanthocyanidin A2 and one or more phospholipids, and methods of treating or preventing atherosclerosis and myocardial and cerebral infarction in a patient by administering the complex of proanthocyanidin A2 and one or more phospholipids, as well as methods of forming such complexes

Abstract: An immunostimulating complex matrix comprising a saponin preparation, a sterol and a phospholipid, the matrix further comprising a metal-chelating moiety capable of binding a protein or polypeptide having at least one chelating amino acid sequence in the presence of metal ions. An immunogenic immunostimulating complex which comprises this matrix and an immunogenic protein or polypeptide having at least one chelating amino acid sequence, the protein or polypeptide being bound to the matrix in the presence of metal ions.

Abstract: An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.

Abstract: The present invention is directed to a method of treating patients with bipolar disorder by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g. a triacylglycerol, which releases free fatty acid after ingestion by a patient.

Abstract: A method of treating or preventing vascular disease in a living organism. The method includes delivering an effective amount of a composition including a sex hormone, anti-hormone, sex-hormone agonist, steroid-hormone inhibitor/antagonist (partial or full), selective estrogen receptor modulator (SERM), or a combination thereof, to an affected area of a living organism.

Abstract: An anti-depressant, mental & emotional stress suppressor and mood improver having a prominent action for decreasing blood cortisol level and serotonin reuptake and has an effect of alleviating symptoms associated with depression and mental & emotional stress of a subject administered with the improver. The improver contains as the effective ingredient a combination of phosphatidy-L-serine and phosphatidic acid, or the salts thereof, comprising at least 20% (w/w) phosphatidy-L-serine and typically within the range of about 20%-40% of phosphatidy-L-serine, out of the total phospholipid content of the composition and at least 3% (w/w) of phosphatidic acid, preferably above about 10% and typically within the range of about 20%-40% of phosphatidic acid, out of the total phospholipid content of the composition.

Abstract: Cryopreserved boar spermatozoa is much less fertile than that of other species, which could be due to damage to sperm membrane lipids during the cryopreservation process. Incorporation of selected lipids improves the survival of boar spermatozoa following cryopreservation. Liposomes were made from lipids extracted from head plasma membrane (HPM) of boar spematozoa or from selected lipids (SL) which contained specific phospholipids. At a fixed lipid concentration, fusion efficiency with spermatozoa as measured by flow cytometry and R18 dequenching was affected by lipid type, sperm concentration and incubation time. SL and HPM improved sperm viability (SYBR-14 and propidium iodide) and motility during cooling to 5C., with SL±egg yolk better than or equal to HPM (P<0.05). Post-thaw, egg yolk showed a strong cryoprotective effect.

Abstract: The invention relates to the treatment of serous otitis media (glue ear). A medicament is disclosed which comprises a surface active phospholipid (SAPL) which is instilled as a powder into the middle ear. The SAPL has an affinity for the surface of the Eustachian tube and forms a film over its surface which prevents or deters reblockage of the tube.

Abstract: The present invention relates to a pharmaceutically acceptable dosage form of water insoluble porphyrins, particularly metal containing porphyrins such as tin porphyrin, which can be complexed with a lipid, reconstituted from a lyophilizate and administrated to a patient in the treatment of cancer and other diseases.

Abstract: This invention herein describes a method of facilitating the entry of drugs into cells and tissues at pharmokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods because through this method, intracellular drug concentrations may reach levels which are orders of magnitude higher than those achieved otherwise. Furthermore, it refines the drug delivery process by allowing therapeutic agents to be directed to certain intracellular structures. This technology is appropriate for use with antiproliferative, antibiotic, antimycotic, antiviral and antineoplastic drugs, in particular in combination with a multiplicity of other emollients and agents to make up topically-active substances such as salves, for rapid and efficient introduction of such agents through the epidermis for treatment of skin diseases and other disorders.

Abstract: Lipids are used as aids in the production of solid drug forms by melt extrusion.